Breaking News, Collaborations & Alliances

Two Cell and Gene Therapies Manufactured at Lonza Houston Reach FDA Approval

Approvals of Zynteglo and Skysona mean that Lonza’s Houston site now supports three commercial CGT products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition industries, said that two additional cell and gene therapies manufactured at its Houston, TX, site have reached commercial approval in Q3 2022. Zynteglo, for the treatment of transfusion-dependent beta-thalassemia; and Skysona, for the treatment of early, active cerebral adrenoleukodystrophy, are both manufactured by bluebird bio of Somerville, MA, and were approved in August and September, respectively. These reg...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters